GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OTCPK:NONOF) » Definitions » Price-to-Owner-Earnings

NONOF (Novo Nordisk AS) Price-to-Owner-Earnings : 19.24 (As of May. 17, 2025)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk AS Price-to-Owner-Earnings?

As of today (2025-05-17), Novo Nordisk AS's share price is $63.29. Novo Nordisk AS's Owner Earnings per Share (TTM) ended in Mar. 2025 was $3.29. It's Price-to-Owner-Earnings for today is 19.24.


The historical rank and industry rank for Novo Nordisk AS's Price-to-Owner-Earnings or its related term are showing as below:

NONOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.66   Med: 23.38   Max: 57.29
Current: 19.26

During the past 13 years, the highest Price-to-Owner-Earnings of Novo Nordisk AS was 57.29. The lowest was 12.66. And the median was 23.38.


NONOF's Price-to-Owner-Earnings is ranked better than
59.46% of 444 companies
in the Drug Manufacturers industry
Industry Median: 24.275 vs NONOF: 19.26

As of today (2025-05-17), Novo Nordisk AS's share price is $63.29. Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $3.40. Therefore, Novo Nordisk AS's PE Ratio (TTM) for today is 18.64.

As of today (2025-05-17), Novo Nordisk AS's share price is $63.29. Novo Nordisk AS's EPS without NRI for the trailing twelve months (TTM) ended in was $3.40. Therefore, Novo Nordisk AS's PE Ratio without NRI for today is 18.64.

During the past 13 years, Novo Nordisk AS's highest PE Ratio without NRI was 50.51. The lowest was 15.30. And the median was 25.89.


Novo Nordisk AS Price-to-Owner-Earnings Historical Data

The historical data trend for Novo Nordisk AS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Price-to-Owner-Earnings Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.13 37.26 35.74 36.74 27.27

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.45 39.93 37.37 27.27 21.22

Competitive Comparison of Novo Nordisk AS's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Price-to-Owner-Earnings falls into.


;
;

Novo Nordisk AS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Novo Nordisk AS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=63.29/3.29
=19.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk AS  (OTCPK:NONOF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Novo Nordisk AS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.